
KalVista Pharma (KALV) Stock Forecast & Price Target
KalVista Pharma (KALV) Analyst Ratings
Bulls say
KalVista Pharmaceuticals is positioned for a favorable outlook due to its differentiated oral therapy, sebetralstat, for treating acute attacks of hereditary angioedema (HAE) which is expected to provide a significant sales opportunity with a conservative estimate of approximately $400 million in worldwide sales at peak. The convenience and efficacy of sebetralstat, especially in adolescent patients, may lead to increased adoption rates as physicians believe that an oral medication will encourage patients to treat more frequent attacks. The company's strategic focus on launching a novel treatment in a stabilized HAE market, combined with encouraging recent clinical data and a high probability of regulatory approval, underscores a positive trajectory for KalVista Pharmaceuticals.
Bears say
KalVista Pharmaceuticals Inc. reported a significant net loss of $44.3 million, translating to a loss of $0.92 per share for the third quarter ended January 31, 2025, highlighting ongoing financial struggles. The company faces considerable risks, including the potential failure of its lead product, sebetralstat, which could hamper future growth prospects, as the existing pipeline lacks alternative candidates to support revenue generation. Additionally, the uncertainty surrounding regulatory approval and market acceptance of sebetralstat, particularly for critical applications such as laryngeal attacks, further exacerbates the financial risks associated with the company’s operations and growth trajectory.
This aggregate rating is based on analysts' research of KalVista Pharma and is not a guaranteed prediction by Public.com or investment advice.
KalVista Pharma (KALV) Analyst Forecast & Price Prediction
Start investing in KalVista Pharma (KALV)
Order type
Buy in
Order amount
Est. shares
0 shares